Related Experiment Video
Updated: Jan 13, 2026

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Pregabalin in Pregnancy: Major Congenital Malformations, Other Birth Outcomes, and Neurodevelopmental Outcomes
1Department of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences, Bangalore, India; Department of Psychiatry, Kasturba Medical College, Manipal Academy of Higher Education, Manipal, India.
Insights
Pregnancy exposure to pregabalin is not linked to major birth defects or adverse outcomes like stillbirth or preterm birth. Further research is needed due to small sample sizes in pregabalin pregnancy studies.
Area of Science:
- Pharmacology
- Obstetrics and Gynecology
- Developmental Pediatrics
Background:
- Pregabalin, a gabapentinoid, functions by inhibiting calcium influx via the α2δ-1 subunit of voltage-gated calcium channels.
- Its approved indications include neuropathic pain, fibromyalgia, seizures, and anxiety disorder, with off-label uses for various other conditions.
- A small percentage of pregnant women may use pregabalin, necessitating an examination of pregnancy outcomes.
Purpose of the Study:
- To evaluate the safety of pregabalin use during pregnancy.
- To assess the association between gestational pregabalin exposure and major congenital malformations.
- To investigate the impact of pregabalin exposure on other significant birth outcomes and neurodevelopmental disorders.
Main Methods:
- A meta-analysis of 7 cohort studies was conducted.
- Data from studies examining pregabalin-exposed pregnancies were synthesized.
- Statistical analyses, including adjusted and unadjusted models, were employed to assess risks.
Main Results:
- Pregabalin exposure in pregnancy was not associated with an increased risk of major congenital malformations.
- Significant risks for outcomes like stillbirth, low birth weight, and preterm birth were generally not observed after adjustment for confounders.
- While some studies indicated potential risks for attention-deficit/hyperactivity disorder and autism spectrum disorder, these were often not significant after adjustment.
Conclusions:
- Gestational exposure to pregabalin does not appear to increase the risk of major congenital malformations.
- Overall, pregabalin use in pregnancy is not linked to significant adverse birth outcomes when adjusted for confounding factors.
- Limitations include small sample sizes in pregabalin-exposed pregnancy cohorts, warranting cautious interpretation and further investigation.
Abstract:
Pregabalin is a gabapentinoid. It does not act on GABA receptors; rather, it inhibits calcium influx into neurons by acting on the α2δ-1 subunit of voltage-gated calcium channels. This reduces release of excitatory neurotransmitters, thereby, perhaps, explaining the sedative, anxiolytic, anticonvulsant, and other properties of the drug. Pregabalin has been approved for neuropathic pain, fibromyalgia, partial-onset seizures, and generalized anxiety disorder, and is used, off-label, for pain in many other contexts and for alcohol use disorder, pruritus, restless legs syndrome, and sleep disorders. It may also be abused. About 0.04%-0.14% of women may use pregabalin during pregnancy. This article examines outcomes of pregnancies that were exposed to pregabalin. A meta-analysis of 7 cohort studies found that, even in unadjusted analysis, pregabalin was not associated with an increased risk of major congenital malformations. This finding was confirmed in later studies; or, if the unadjusted risk was significantly elevated, it was no longer so in adjusted analysis. Many studies found that anytime gestational exposure to pregabalin was not associated with a significantly elevated risk of other important birth outcomes such as stillbirth, low birth weight, preterm birth, small for gestational age, low Apgar score, and microcephaly; or the risks were elevated before but not after adjustment for covariates and confounds; or the risks were not significant relative to disease controls. Similarly, studies found that anytime gestational exposure to pregabalin was associated with no increase in risk, or with a significantly increased risk of attention-deficit/ hyperactivity disorder and related disorders, autism spectrum disorder and related disorders, and intellectual disability before but not after adjustment for covariates and confounds. As a limitation, pregabalin-exposed pregnancy sample sizes were small in all studies. On the positive side, safety impressions were obtained despite negligible adjustment for genetic, illness behavior, and environmental confounds.
More Related Videos
07:36Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
Published on: November 20, 2015
15:27Construction of Vapor Chambers Used to Expose Mice to Alcohol During the Equivalent of all Three Trimesters of Human Development
Published on: July 13, 2014
Related Concept Videos
Teratogenicity
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Neurulation
Antiepileptic Drugs: Glutamate Antagonists